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Abstract The possible modulation of the glutamate transporter
EAAC1 by a class A G protein-coupled receptor was studied in
transfected C6 glioma cells stably expressing the high-a⁄nity
neurotensin receptor NTS1. Brief exposure (5 min) to neuro-
tensin increased Na+-dependent D-[3H]aspartate uptake by
about 70%. The e¡ect of neurotensin was found to result from
an increase in cell surface expression of EAAC1 and accord-
ingly, cytochalasin D and colchicine were shown to block the
e¡ect of neurotensin on aspartate uptake, suggesting that the
cytoskeleton participates in this regulation. Neither protein ki-
nase C nor phosphatidylinositol 3-kinase activities, two intra-
cellular signaling pathways known to modulate EAAC1, was
required for EAAC1-mediated aspartate transport regulation
by neurotensin. Together, these results provide evidence for an
acute regulation of EAAC1 tra⁄cking after activation of a G
protein-coupled receptor. 4 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Glutamate is the major mediator of excitatory signals in the
mammalian brain [1]. Within glutamatergic synapses, a vari-
ety of membrane proteins participate in the regulation of the
intensity and length of postsynaptic excitation. Diverse cell
surface glutamate receptors play determining roles in ensuring
signal transmission whereas speci¢c glutamate transporters
contribute to reduce the glutamate concentration in the syn-
aptic cleft. Although many studies have been focused on the
activity of glutamate receptors, modulation of transporter
function has recently received much more attention as it is
now clearly established that glutamate uptake is required to
prevent glutamate-mediated excitotoxic injuries [2^4].
To date, ¢ve high-a⁄nity Naþ-dependent glutamate trans-
porters have been characterized: the glial GLT-1 and
GLAST, the neuronal EAAC1 and EAAT4, and the retinal
transporter EAAT5 [5]. Many reports have shown that trans-
porters for diverse neurotransmitters are subject to regulation,
supporting evidence for the possible cross-talk between these
transporters and other proteins in the same synaptic element.
Accordingly, the activity and cell surface expression of gluta-
mate transporters can be acutely altered by manipulating in-
tracellular signaling pathways, including protein kinases, ni-
tric oxide synthesis, and arachidonic acid production [6^8]. In
C6 glioma cells, protein kinase C (PKC) activation was shown
to increase the activity and cell surface expression of EAAC1,
whereas phosphatidylinositol 3-kinase (PI3-K) inhibition leads
to a decrease in these parameters [6,9].
In order to evaluate the possible involvement of G protein-
coupled receptors (GPCR) in the modulation of EAAC1 ac-
tivity, we have used a model of transfected C6 glioma cells
expressing the high-a⁄nity neurotensin (NT) receptor (NTS1
receptor) as a prototypical member of the class A GPCR
family known to preferentially activate Gq=11-type G proteins,
leading to the activation of phospholipase C (PLC) and sub-
sequent mobilization of intracellular Ca2þ and activation of
PKC. In this model, brief exposure to NT was found to dra-
matically increase cell surface expression of EAAC1 and glu-
tamate uptake through a PKC-independent mechanism. This
study is the ¢rst report on the regulation of EAAC1 tra⁄ck-
ing and activity expression after activation of a GPCR.
2. Materials and methods
2.1. Materials
All radioisotopes were purchased from Amersham Pharmacia Bio-
tech (Roosendaal, The Netherlands). Sulfo-NHS-biotin and immuno-
pure immobilized monomeric streptavidin were from Pierce (Perbio
Science, Erembodegem-Aalst, Belgium). L-Aspartate, cytochalasin D,
colchicine, wortmannin, D-sphingosine, phorbol 12-myristate 13-ace-
tate (PMA) and phenylarsine oxide (PAO) were from Sigma (Bornem,
Belgium). H89, KN-62, PD98059, Ro-31-8220 were obtained from
Calbiochem (Merck Eurolab, Leuven, Belgium).
2.2. Cell culture
Rat C6 glioma cells expressing the NTS1 receptor were obtained by
transfection (calcium phosphate co-precipitation method) using the
rat NTS1 cDNA sequence inserted in the expression vector pcDNA3.
Transfected C6 cells were selected in the presence of 600 Wg/ml Ge-
neticin (G418). The clone that displayed the highest [3H]NT binding
(Bmax and KD values of 1.39E0.63 pmol/mg protein and 0.26E 0.03
nM, respectively) was expanded for the study presented here. Cells
were routinely grown in Dulbecco’s modi¢ed Eagle’s medium (Invi-
trogen) supplemented with 10% fetal bovine serum, 20 Wg/ml proline,
100 U/ml penicillin and 100 Wg/ml streptomycin. All cultures were
maintained at 37‡C in a water-saturated atmosphere containing 5%
CO2.
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2.3. Measurement of Naþ-dependent transport activity
For uptake assays, cells were grown on 24-well plates. At 80%
con£uence, plates were placed at the surface of a 37‡C water bath,
rinsed twice with 1 ml of preheated bu¡er (25 mM HEPES pH 7.4,
4.8 mM KCl, 1.2 mM KH2PO4, 1.3 mM CaCl2, 1.2 mM MgSO4, and
6 mM glucose) supplemented with either 140 mM NaCl or 140 mM
choline chloride and then treated with drugs or vehicle. As in the
majority of studies concerning glutamate transporters, aspartate, a
non-metabolizable transported analog of glutamate, was used to eval-
uate the uptake activity [5,10]. Except for saturation studies,
D-[3H]aspartate was used at a ¢nal concentration of 30 nM. For
saturation studies, D-[3H]aspartate (30 nM) was diluted with unlabeled
L-aspartate to achieve ¢nal aspartate concentrations of 1^200 WM.
Inhibitors were added 15 min before the addition of NT. The uptake
was stopped after 6 min with three rinses of ice-cold choline bu¡er (in
these experimental conditions, uptake was found to be linear up to
20 min). The cells were solubilized with 0.5 ml of 1 N NaOH. 200 Wl
of the radioactive lysate was counted in a scintillation counter. After
experiments, protein assays were achieved in order to ensure that any
drugs a¡ect the protein content in the wells [11]. The speci¢c Naþ-
dependent uptake was estimated by subtracting the values obtained
with cells incubated in the choline chloride-containing bu¡er.
2.4. Cellular tra⁄cking of glutamate EAAC1 transporter
Biotinylation experiments were performed as previously described
[6] with minor modi¢cations. C6 glioma cells were grown in six-well
plates to at least 80% con£uence. After rinsing with phosphate-bu¡-
ered saline (PBS) containing 0.1 mM Ca2þ and 0.1 mM Mg2þ, cells
were incubated with 0.8 ml of sulfo-NHS-biotin (1.5 mg/ml in PBS^
Ca2þ/Mg2þ) for 30 min at 4‡C with mild shaking. Thereafter, cells
were rinsed twice with cold PBS^Ca2þ/Mg2þ containing 100 mM gly-
cine and incubated with the same solution for 45 min at 4‡C to
quench the unbound biotin reagent. Cell lysis was performed with
radioimmunoprecipitation assay (RIPA) bu¡er (100 mM Tris^HCl,
pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% sodium dodecyl sulfate) supplemented with pro-
tease inhibitors (250 WM phenylmethylsulfonyl £uoride and protease
inhibitor cocktail from Sigma) bu¡er for 1 h at 4‡C with brisk shak-
ing. After centrifugation at 16 000Ug at 4‡C for 20 min, 150 Wl super-
natant was incubated with an equal volume of streptavidin bead sus-
pension for 1 h at room temperature. After centrifugation (15 min at
16 000Ug at 4‡C), the supernatant was collected for analysis of the
non-biotinylated intracellular fraction while the pelleted biotinylated
cell surface proteins were washed four times with 0.8 ml of RIPA
bu¡er and resuspended in 50 Wl of Laemmli bu¡er containing
50 mM dithiothreitol. After 15 min centrifugation at 16 000Ug, super-
natants were stored at 320‡C until analyzed.
2.5. Immunoblot analyses
Samples were thawed and boiled for 5 min. Cell extracts were
analyzed by 10% SDS^PAGE according to Laemmli [12]. After elec-
troblotting to nitrocellulose membranes, proteins were probed with
a⁄nity-puri¢ed anti-EAAC1 (0.5 Wg/ml) (ADI, USA) and subse-
quently, the antigen^antibody complex was detected with a horserad-
ish peroxidase-conjugated goat anti-rabbit IgG secondary antibody
(1:3000) (Sigma). The immunoreactive proteins were detected with
enhanced chemiluminescence reagents. Quantitative densitometry
analysis of the autoradiograms was performed using a digital image
analysis system (MCID 4; Imaging Research, St. Catharines, ON,
Canada).
2.6. Statistical analysis
Statistical di¡erences were determined by Student’s t-test for two-
group comparison. For multiple comparisons, data were analyzed by
one-way ANOVA followed by the Newman^Keuls test.
3. Results
3.1. E¡ect of NT on D-[3H] aspartate uptake activity
Exposure of C6-NTS1 cells to 100 nM NT for 5 min mark-
edly increased the speci¢c Naþ-dependent L-[3H]glutamate
(30 nM) uptake by 82% as compared to non-treated cells
(not shown). Similarly, the same treatment caused a 95% in-
crease in the speci¢c uptake of D-[3H]aspartate (30 nM). Fur-
ther determination of the e¡ect of NT was obtained by non-
linear analysis of the speci¢c uptake of isotopic dilutions of
D-[3H]aspartate/L-aspartate revealing that the 5 min NT (100
nM) treatment increased the uptake capacity by 67% (Vmax
values of 174E 21 and 292E 40 pmol/mg protein/min for con-
trol and NT-treated cells, respectively; n=6, P6 0.001, paired
Student’s t-test) with no modi¢cation of the a⁄nity for the
substrate (Km values of 7.86E 0.65 and 7.34 E 0.56 WM, re-
spectively) (Fig. 1A). The e¡ect of NT on aspartate uptake
Fig. 1. E¡ect of NT on Naþ-dependent D-[3H]aspartate uptake in
C6-NTS1 cells. A: Saturation curve for aspartate uptake measured
in C6-NTS1 cells treated for 5 min with NT (closed symbols) or ve-
hicle (open symbols). Data shown correspond to meansES.E.M.
from six experiments performed in triplicate. B: E¡ect of pretreating
C6-NTS1 cells with increasing concentrations of NT for 5 min on
aspartate uptake. Inset shows the e¡ect of NT on aspartate uptake
in non-transfected C6 cells. Data are expressed as percent of control
and correspond to meansES.E.M. of four independent experiments
performed in triplicate. C: E¡ect of the PKC inhibitor Ro-31-8220
on NT- and PMA-stimulated aspartate uptake in C6-NTS1 cells.
Data shown are meansES.E.M. of at least four independent experi-
ments performed in triplicate. ***P6 0.001, signi¢cant di¡erence
versus corresponding control, n.s. denotes no signi¢cant di¡erence
(one-way ANOVA followed by Newman^Keuls test).
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was concentration-dependent (Fig. 1B). The maximal e¡ect
was obtained when cells were incubated in the presence of
100 nM NT and the pEC50 value for NT was 8.27 E 0.08, in
the same range as the potency of NT at mediating the func-
tional activation of NTS1 receptor (NT was shown to stim-
ulate phosphoinositide hydrolysis with a pEC50 value of
9.05E 0.07). As expected, the e¡ect of NT was not observed
when tested on non-transfected C6 cells (Fig. 1B, inset), fur-
ther con¢rming the involvement of the NTS1 receptor.
3.2. Role of intracellular signaling cascades in the stimulation
of EAAC1-mediated aspartate uptake by NT
Activation of PKC by phorbol ester was previously shown
to modulate EAAC1 activity in C6 glioma cells. Accordingly,
exposure of C6-NTS1 cells to PMA resulted in a robust in-
crease in speci¢c aspartate uptake (97% increase as compared
to control, P6 0.001) that was completely prevented when
cells were preincubated with the speci¢c PKC inhibitor
Ro-31-8220 (0.5 WM) (Fig. 1C). In contrast, this inhibitor
(used at the same concentration) failed to block the NT-medi-
ated increase in aspartate uptake. Similar results were ob-
tained with D-sphingosine, another speci¢c PKC inhibitor
(Table 1). Based on two recent studies indicating the possible
involvement of PI3-K in the regulation of EAAC1 in C6 cells
[6,9], we also evaluated the possible implication of this enzyme
in the modulation of aspartate uptake by NT. As previously
reported, inhibition of this enzyme with wortmannin (100 nM)
was found to decrease the basal activity of EAAC1 to 37% of
control (Table 1). However, when wortmannin-pretreated cells
were exposed to NT, the neuropeptide was found to signi¢-
cantly increase the residual aspartate uptake (137% increase as
compared to control wortmannin-pretreated cells, P6 0.001).
These results indicate that PKC and PI3-K activities are not
involved in the rapid e¡ect of NT on aspartate uptake in
C6-NTS1 cells.
Although NTS1 receptor is known to preferentially mediate
intracellular responses through Gq=11-type G proteins, multi-
ple studies have demonstrated functional coupling with Gi=o-
and Gs-type G proteins [13,14], leading to additional signaling
cascades, including modulation of adenylyl cyclase and induc-
tion of mitogen-activated protein kinases (MAPK). As shown
in Table 1, neither the PKA inhibitor H89, nor the MAPK
inhibitor PD98059 signi¢cantly prevented the e¡ect of NT.
Similarly, KN-62, an inhibitor of calcium calmodulin-depen-
dent protein kinase II, and L-NAME, a nitric oxide synthase
inhibitor, were unable to block the NT-stimulated aspartate
uptake in C6-NTS1 cells.
3.3. E¡ect of NT on cell surface expression of EAAC1
Previous studies revealed that both alteration in transporter
activity and cell surface expression may contribute to the reg-
ulation of EAAC1 [6,9]. In order to study the e¡ect of NT on
the membrane tra⁄cking of EAAC1, we biotinylated cell sur-
face proteins using a membrane-impermeant biotin ester and
Table 1
E¡ects of signal transduction inhibitors on NT-stimulated D-[3H]aspartate uptake
Inhibitor NT Inhibitor+NT
D-Sphingosine (10 WM) 115E 6 183E 10 186E 11
L-NAME (1 WM) 122E 9 183E 10 176E 11
H89 (500 nM) 99E 3 179E 14 155E 6
KN-62 (1 WM) 85E 7 179E 14 156E 12
PD98059 (10 WM) 98E 3 141E 5 148E 7
Wortmannin (100 nM) 37E 1 212E 7 88E 7
C6-NTS1 cells were pretreated with either vehicle or inhibitor for 15 min before exposure to NT (100 nM). The uptake assay was performed
5 min later. In all cases, no statistical di¡erence was observed between the groups preincubated with inhibitors plus NT and those preincubated
with NT alone. The two groups were statistically di¡erent from the controls (vehicles) and the groups preincubated with inhibitor alone (one-
way ANOVA followed by the Newman^Keuls test). Values are percentages of Naþ-dependent D-[3H]aspartate uptake in control wells preincu-
bated in the absence of NT or inhibitor and represent meansES.E.M. of at least three independent experiments performed in triplicate.
Fig. 2. Modulation of cell surface expression of EAAC1 by NT.
Biotinylation of membrane proteins was performed to distinguish
cell surface (biotinylated protein fractions) and intracellular proteins
(non-biotinylated protein fractions) as described in Section 2.
A: Non-transfected C6 cells. B: C6-NTS1 transfected cells. Typical
autoradiograms are shown in the lower panels (arrows indicate the
band corresponding to the EAAC1 transporter) whereas upper pan-
els show the quantitation by gray-scale densitometry of the EAAC1
immunoreactivity (meansES.E.M. from three di¡erent experiments).
*P6 0.05; **P6 0.01; ***P6 0.001 as compared to control (one-
way ANOVA followed by Newman^Keuls test).
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after recovery of biotinylated EAAC1 using streptavidin^aga-
rose beads, the transporters expressed at the plasma mem-
brane were detected by immunoblotting (see Fig. 2). The
band corresponding to the biotinylated EAAC1 was identi¢ed
with an apparent molecular weight ofV68 kDa. After remov-
al of biotinylated material, EAAC1 immunoreactive proteins
were detected in the supernatant, indicating the existence of
intracellular EAAC1. This result is in good agreement with
those demonstrating the cytoplasmic localization of EAAC1
in brain tissues [15,16]. Incubation of non-transfected C6 cells
with PMA (500 nM, 30 min) caused an increase in the inten-
sity of EAAC1 immunoreactivity in the biotinylated fraction
(Fig. 2A) that correlated with a signi¢cant decrease in the
corresponding non-biotinylated (intracellular) fraction (Fig.
2A). As expected, no change in the intensity of the biotinyl-
ated and intracellular EAAC1-positive fractions was detected
when non-transfected C6 cells were challenged with NT (Fig.
2A). Similarly, incubation of C6-NTS1 cells with NT for 5 or
15 min resulted in a modi¢cation in the proportion of bio-
tinylated and non-biotinylated EAAC1 levels, with the highest
e¡ect of NT observed after 15 min (about 80% increase as
compared to control values) (Fig. 2B). Based on these obser-
vations, we investigated whether such redistribution of
EAAC1 could explain the e¡ect of NT on aspartate uptake,
using inhibitors of cytoskeletal organization. As shown in Fig.
3, colchicine, a disrupting agent of microtubule formation,
and cytochalasin D, an inhibitor of actin polymerization,
were without e¡ect on basal aspartate uptake but impaired
the stimulatory e¡ect of NT. Similarly, PAO, which blocks
both externalization and internalization processes, dramati-
cally inhibited the e¡ect of NT on aspartate uptake. These
results suggest that the increase in aspartate uptake induced
by NT results from an alteration in the EAAC1 tra⁄cking
which requires an intact cytoskeleton.
4. Discussion
The activity and expression of many membrane transport-
ers are known to be regulated through phosphorylation-de-
pendent pathways [17^19]. In the case of the glutamate trans-
porter EAAC1, recent studies have highlighted the possible
implication of both PKC and PI3-K in the alteration of glu-
tamate uptake by in£uencing its cell surface expression [6,9].
However, the physiological stimuli responsible for the activa-
tion of these kinases have not been identi¢ed and no data are
available concerning the possible involvement of endogenous
transmission systems acting via GPCRs in the regulation of
EAAC1. In order to study such regulation, we established
transfected C6 cells expressing the NTS1 receptor and exam-
ined whether its activation modulates the activity and/or cell
surface expression of EAAC1. Exposure of C6-NTS1 cells to
NT induces an increase in EAAC1-mediated D-[3H]aspartate
uptake within 5 min. Since the NTS1 receptor is preferentially
coupled to PLC activation, most responses to NT are usually
attributed to the intracellular Ca2þ mobilization [20] and PKC
translocation [21,22]. However, in the present study, the PKC
inhibitors Ro-31-8220 and D-sphingosine failed to prevent the
e¡ect of NT indicating that PKC is not the pathway required
for the modulation of aspartate transport by NT. Similarly,
the PI3-K inhibitor wortmannin was ine¡ective in blocking
the e¡ect of NT on the residual aspartate uptake.
The regulation of the uptake of many neurotransmitters
involves the rapid translocation of intracellular pools of spe-
ci¢c transporters [23^25]. Accordingly, the rapid modulation
of EAAC1 activity is incompatible with the de novo synthesis
of this transporter and our data suggest that the alteration of
aspartate transport observed after NT treatment is the con-
sequence of an increased density of cell surface EAAC1 trans-
porters. Thus the e¡ect of NT on aspartate uptake a¡ects the
maximal velocity of the transport but not the a⁄nity for the
substrate. Our biotinylation experiments indicate that the pro-
portion of extracellularly exposed EAAC1 signi¢cantly in-
creases after a brief exposure to NT, an e¡ect that is compat-
ible with the time required for changes related to tra⁄cking of
this transporter. Moreover, we demonstrate that the NT-in-
duced aspartate transport was completely blocked by colchi-
cine suggesting the participation of the microtubule network
in the modulation of the cell distribution of EAAC1 by NT.
The inhibitory e¡ect of cytochalasin D, which impairs actin
polymerization, promoting disruption of the cytoskeleton, in-
dicates that the latter is also involved in the NT-induced
translocation of EAAC1 to the cell surface.
Based on these observations and since none of the classical
second messenger pathway inhibitors used were e¡ective in
preventing the e¡ect of NT, one could suggest that cytoskel-
etal elements may participate in the interaction between
EAAC1 and other intracellular regulatory proteins modulated
by GPCRs. For instance, it has been demonstrated that tubu-
lin directly interacts with GPCR kinases for which it consti-
tutes a potential substrate [26,27]. Indeed, it has been clearly
suggested that GPCRs or G proteins could directly interact
with cytoskeletal elements [28,29] and modulate cytoskeletal
dynamics and intracellular tra⁄cking [28,30,31]. These func-
tional interactions bring further complexity to the intracellular
signals triggered by GPCR activation and could help to better
understand the PKC- or PI3-K-independent mechanisms in-
volved in the regulation of EAAC1 transporter activity by
Fig. 3. E¡ect of colchicine (10 WM), PAO (10 WM) or cytochalasin
D (30 WM) on basal and NT-stimulated aspartate uptake in C6-
NTS1 cells. Cells were pretreated with the drugs for 15 min. There-
after, NT (100 nM) was added and uptake assay was performed
after 5 min. Results (percent of control) correspond to means
ES.E.M. of at least three independent experiments performed in
triplicate. *P6 0.05; **P6 0.01; ***P6 0.001 as compared to the
corresponding control; ##P6 0.01 as compared to the NT-treated
cells (one-way ANOVA followed by Newman^Keuls test).
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these membrane receptors. Further studies are required to
clarify such mechanisms that allow the rapid and reversible
mobilization of EAAC1 transporter molecules in response to
the activation of a Gq=11-coupled receptor and thereby partic-
ipate in the control of the extracellular levels of glutamate and
neuronal excitation
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